THC Crossover Study (TRDRP)
Cardiovascular Effects of Cannabis Compared to Tobacco Use
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Lisa Lawrence
- Phone Number: (415) 608-4864
- Email: Lisa.Lawrence@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
San Francisco, California, United States, 94110
- Zuckerberg San Francisco General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy on the basis of medical history and limited physical examination, as described below:
Heart rate < 105 beats per minute (BPM); Systolic Blood Pressure < 160 and > 90*; Diastolic Blood Pressure < 100 and > 50*
*Considered out of range if both machine and manual readings are above/below these thresholds.
- Current regular user of cannabis who smokes cannabis as joint or blunt at least 3 times a week for past 3 months
- History of cannabis vaporizer use or willingness to use the vaporizer in the study
- Current tobacco cigarette use who smokes ≥ 5 cigarettes per day
- Saliva cotinine ≥ 50 ng/ml
- Test positive for D-9-tetrahydrocannabinol (THC) at screening and self-report of cannabis use
Exclusion Criteria:
- Unstable medical conditions:
Heart disease; Uncontrolled hypertension; Thyroid disease (okay if controlled with medication); Diabetes; Hepatitis B or C or Liver disease; Glaucoma; Prostatic hypertrophy
- Psychiatric conditions:
Current or past schizophrenia, and/or current or past bipolar disorder; Adult onset attention deficit hyperactivity disorder (ADHD); Participants with current or past depression and/or anxiety disorders will be reviewed by the study physician and considered for inclusion; History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per study physician's approval
- Concurrent regular use of smokeless tobacco or pipes [occasional users of these products may be enrolled if they agree to abstain from their use during the period of the study]
- Medications:
Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, dexamethasone, phenobarbital, and other anticonvulsant drugs).; Concurrent use of nicotine-containing medications; Psychiatric medications: current regular use of any psychiatric medications with the exception of Selective Serotonin Reuptake Inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) and current evaluation by the study physician that the participant is otherwise healthy, stable, and able to participate.
- Other/Misc. Chronic Health Conditions:
Oral thrush; Fainting; Untreated thyroid disease; Other "life threatening illnesses" as per study physician's discretion
- Pregnancy:
Pregnancy (self-reported and urine pregnancy test); Breastfeeding (determined by self-report)
- Drug/Alcohol Dependence:
Alcohol or illicit drug dependence within the past 12 months with the exception of those who have recently completed an alcohol/drug treatment program; Positive toxicology test at the screening visit (THC & prescribed medications okay); Methadone replacement therapy
- Concurrent participation in another clinical trial
- Inability to communicate in English
- History of marijuana-induced psychosis or paranoia after smoking marijuana
- Scoring a 2 or higher on the Severity of Dependence Scale for cannabis use
- Planning to quit smoking or vaping within the next 60 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Smoked Cannabis, Vaped Cannabis, or Tobacco Cigarette
|
Cannabis will be purchased by the participants and reimbursed the full cost by the study.
Participants will be asked to purchase enough to last 2 full days of use.
To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco).
Receipt must be provided to study staff.
Cannabis will be purchased by the participants and reimbursed the full cost by the study.
Participants will be asked to purchase enough to last 2 full days of use.
To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco).
Receipt must be provided to study staff.
All participants will use the study-provided PAX® (PAX 2) dry herb vaporizer, one of the most popular handheld vaporizers.
Tobacco cigarettes of participants' choice (usual brand) will be provided by research staff for use on the study.
|
|
Other: Either of the 2 remaining products
|
Cannabis will be purchased by the participants and reimbursed the full cost by the study.
Participants will be asked to purchase enough to last 2 full days of use.
To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco).
Receipt must be provided to study staff.
Cannabis will be purchased by the participants and reimbursed the full cost by the study.
Participants will be asked to purchase enough to last 2 full days of use.
To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco).
Receipt must be provided to study staff.
All participants will use the study-provided PAX® (PAX 2) dry herb vaporizer, one of the most popular handheld vaporizers.
Tobacco cigarettes of participants' choice (usual brand) will be provided by research staff for use on the study.
|
|
Other: Remaining product
|
Cannabis will be purchased by the participants and reimbursed the full cost by the study.
Participants will be asked to purchase enough to last 2 full days of use.
To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco).
Receipt must be provided to study staff.
Cannabis will be purchased by the participants and reimbursed the full cost by the study.
Participants will be asked to purchase enough to last 2 full days of use.
To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco).
Receipt must be provided to study staff.
All participants will use the study-provided PAX® (PAX 2) dry herb vaporizer, one of the most popular handheld vaporizers.
Tobacco cigarettes of participants' choice (usual brand) will be provided by research staff for use on the study.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peak plasma concentration
Time Frame: Day 1 of each arm
|
To assess the differences between smoked and vaped cannabis, we will determine maximum plasma THC concentration (Cmax) using plasma THC concentrations from the standardized sessions.
|
Day 1 of each arm
|
|
Time to peak plasma concentration
Time Frame: Day 1 of each arm
|
To assess the differences of these variables between smoked and vaped cannabis, we will determine the time to max concentration (Tmax) using plasma THC concentrations from the standardized sessions.
|
Day 1 of each arm
|
|
Area under the plasma concentration versus time curve (AUC)
Time Frame: Day 1 of each arm
|
To assess the differences of these variables between smoked and vaped cannabis, we will determine the AUC using plasma THC concentrations from the standardized sessions.
|
Day 1 of each arm
|
|
Subjective effects between cannabis products using the Marijuana Cravings Questionnaire
Time Frame: Days 1-2 of each arm
|
We will assess measures from the Marijuana Cravings Questionnaire (MCQ) and compare them between smoked and vaped cannabis.
|
Days 1-2 of each arm
|
|
Subjective effects between cannabis products using the Visual Analog Scale
Time Frame: Days 1-2 of each arm
|
We will assess measures from the Visual Analog Scale (VAS) and compare them between smoked and vaped cannabis.
|
Days 1-2 of each arm
|
|
Subjective effects between cannabis products using the Drug Effects Questionnaire
Time Frame: Days 1-2 of each arm
|
We will assess measures from the Drug Effects Questionnaire (DEQ) and compare them between smoked and vaped cannabis.
|
Days 1-2 of each arm
|
|
Max change of expired carbon monoxide
Time Frame: Days 1-2 of the cannabis arms
|
We will examine differences in max change of expired carbon monoxide (CO) from day 1 between smoked and vaped cannabis.
|
Days 1-2 of the cannabis arms
|
|
Area under the expired carbon monoxide (CO) curve (AUC)
Time Frame: Days 1-2 of the cannabis arms
|
We will examine differences in integrated AUC of expired carbon monoxide from day 1 between smoked and vaped cannabis.
|
Days 1-2 of the cannabis arms
|
|
Differences in metabolites of volatile organic compounds (VOCs)
Time Frame: Days 1-2 of the cannabis arms
|
We will examine differences in 12-hour urine mercapturic acid metabolites of volatile organic compounds (from day 2) between smoked and vaped cannabis.
|
Days 1-2 of the cannabis arms
|
|
Exposure to toxicants between cannabis products
Time Frame: Days 1-2 of the cannabis arms
|
We will also examine how measures of use (number of puss, amount use, number of use episodes) correlate with biomarker concentrations between smoked and vaped cannabis.
|
Days 1-2 of the cannabis arms
|
|
Cardiovascular effects between cannabis products using heart rate as a measure
Time Frame: Day 1 of each arm
|
We will compare maximum change in heart rate as well as an integrated measure of heart rate over the first 30 minutes after the standardized session (day 1) between smoked and vaped cannabis.
|
Day 1 of each arm
|
|
Cardiovascular effects between cannabis products using epinephrine as a measure
Time Frame: Day 2 of each cannabis arm
|
Urine catecholamine excretion, particularly epinephrine, will be examined in 12-hour urines and compared between smoked and vaped cannabis.
|
Day 2 of each cannabis arm
|
|
Cardiovascular effects between cannabis products using platelet activation as a measure
Time Frame: Day 2 of each cannabis arm
|
We will examine differences in blood and urine biomarkers of platelet activation between smoked and vaped cannabis.
|
Day 2 of each cannabis arm
|
|
Cardiovascular effects between cannabis products using oxidant stress as a measure
Time Frame: Day 2 of each cannabis arm
|
We will examine differences in blood and urine biomarkers of oxidant stress between smoked and vaped cannabis.
|
Day 2 of each cannabis arm
|
|
Cardiovascular effects between cannabis products using endothelial dysfunction as a measure
Time Frame: Day 2 of each cannabis arm
|
We will examine differences in blood and urine biomarkers of endothelial dysfunction and inflammation between smoked and vaped cannabis.
|
Day 2 of each cannabis arm
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Toxicant exposure between smoked tobacco and cannabis using expired carbon monoxide as the measure
Time Frame: Day 1 of each arm
|
We will examine differences in expired carbon monoxide (CO) from day 1 (both max change and integrated AUC of expired CO) between smoked tobacco and cannabis.
|
Day 1 of each arm
|
|
Toxicant exposure between smoked tobacco and cannabis using mercapturic acid as the measure
Time Frame: Day 2 of each arm
|
We will examine differences in 12-hour urine mercapturic acid metabolites of volatile organic compounds (VOCs) (from day 2) between smoked tobacco and cannabis.
|
Day 2 of each arm
|
|
Toxicant exposure between smoked tobacco and cannabis using use as a measure
Time Frame: Days 1-2 of each arm
|
We will also examine how measures of use (number of puffs, amount use, number of use episodes) correlate with biomarker concentrations between smoked tobacco and cannabis.
|
Days 1-2 of each arm
|
|
Cardiovascular effects between smoked tobacco and cannabis using heart rate as a measure
Time Frame: Day 1 of each arm
|
We will compare maximum change in heart rate as well as an integrated measure of heart rate over the first 30 minutes after the standardized session (day 1) between smoked tobacco and cannabis.
|
Day 1 of each arm
|
|
Cardiovascular effects between smoked tobacco and cannabis using epinephrine as a measure
Time Frame: Day 2 of each arm
|
Urine catecholamine excretion, particularly epinephrine, will be examined in 12-hour urines.
|
Day 2 of each arm
|
|
Cardiovascular effects between smoked tobacco and cannabis using platelet activation as a measure
Time Frame: Day 2 of each arm
|
We will examine differences in blood and urine biomarkers of platelet activation between smoked tobacco and cannabis.
|
Day 2 of each arm
|
|
Cardiovascular effects between smoked tobacco and cannabis using oxidant stress as a measure
Time Frame: Day 2 of each arm
|
We will examine differences in blood and urine biomarkers of oxidant stress between smoked tobacco and cannabis.
|
Day 2 of each arm
|
|
Cardiovascular effects between smoked tobacco and cannabis using endothelial dysfunction as a measure
Time Frame: Day 2 of each arm
|
We will examine differences in blood and urine biomarkers of endothelial dysfunction and inflammation between smoked tobacco and cannabis.
|
Day 2 of each arm
|
|
Puffing behaviors across all products
Time Frame: Days 1-2 of each arm
|
We will examine how puffing behaviors are different between all products (smoked and vaped cannabis, as well as with smoked tobacco cigarettes) and how they correlate with toxicant biomarker concentrations.
Vaping topography measures will be obtained from frame by frame analysis of high definition videos.
|
Days 1-2 of each arm
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Gideon St. Helen, PhD, University of California, San Francisco
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 17-24117
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use
-
NCT06438549RecruitingTobacco Use | Tobacco Use Cessation | Tobacco Use in Childbirth
-
NCT07431619Not yet recruitingTobacco Cessation
-
NCT07148232RecruitingTobacco Cessation | Tobacco Use | Tobacco Use Cessation | Tobacco Dependence | Tobacco Abstinence
-
NCT06851936RecruitingTobacco Use | Nicotine Use
-
NCT04107779CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, Electronic
-
NCT04143256CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, Electronic
-
NCT03645941CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, Cigarette
-
NCT06637358CompletedSmokeless Tobacco Cessation
-
NCT03238456CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Cigarette
-
NCT06927700CompletedTobacco Product Beliefs and Use
Clinical Trials on Smoked Cannabis
-
NCT05868213CompletedCannabis | Electroencephalography | Memory
-
NCT00248378Completed
-
NCT06669585CompletedCannabis | Electroencephalography | Memory
-
NCT05865470RecruitingPain | Abuse, Drug | Intoxication; Cannabinoids
-
NCT02177513Completed
-
NCT03491384CompletedInflammation | Anxiety Disorders | Anxiety | Inflammatory Response | Anxiety Generalized | Anxiety Chronic
-
NCT06059677RecruitingDriving Impaired | Cannabis Smoking
-
NCT04693884CompletedCannabis | Cardiovascular Risk Factor